Industry Laments UK Decision To Go Ahead With ‘Unprecedented’ Sales Repayments

 
• By Leela Barham

The UK government has confirmed plans to raise payments made by drug companies in the statutory scheme for branded medicines to 24.4% for 2023, despite clear warnings from industry that the approach is unsustainable and jeopardizes the delivery of the government's ambitions for life sciences in the post-Brexit UK.

Plenty of capsules and pills laying on a flag of Great Britain
The UK drug pricing system involves a framework of repayments by industry • Source: Shutterstock

More from Europe

More from Geography